Amyloid Beta 1-42 Pre-formed Fibrils (PFFs)
The Amyloid Beta 1-42 Pre-formed Fibrils (PFFs) is For Research Use Only
Sizes: 100 µg, 2 x 100 µg, 5 x 100 ug
Alternative Names: Abeta Pre-formed Fibrils Protein, Abeta peptide, Amyloid beta peptide, Beta amyloid peptide, amyloid beta precursor protein peptide, APP, Abeta Protein PFF,
Research Areas: Alzheimer’s Disease, Amyloid, Neurodegeneration, Neuroscience
Cellular Localization: Cell membrane, Intracellular Vesicles
Sequence References: Gene ID: 351; Swiss Prot: P05067
Our amyloid beta peptide 1-42 (Aβ42) Pre-formed Fibrils are generated from Amyloid Beta Peptide 1-42 pre-treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) using a previously published method. Our Aβ42 fibrils present as long strands when observed under TEM and AFM, and have a unique high molecular weight signal on a Western Blot with an anti-amyloid beta antibody. Our Aβ42 fibrils were also demonstrated to be toxic to primary rat cortical neurons in a dose-dependent manner after an initial sonication step. In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer’s disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation. Soluble Aβ oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function. Aβ oligomers generated in vitro were toxic to PC12 cells and SH-SY5Y cells. Aβ was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients and accumulations of Aβ were shown to be associated with lower survival rates in Parkinson’s disease patients with dementia.